HC Wainwright reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 14.78%, which has investors questioning if this is right time to sell.

Fellow-KI researchers Anders Kvanta and Fredrik Lanner have been awarded a grant of SEK 10 million from the Promobilia ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its ...

The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration ...

This system is delivered into retinal cells using modified viral vectors. The goal is to correct the most common mutation associated with Stargardt disease. The effectiveness of this technique was ...

For a number of cells, the researchers were able to observe in retinal tissue preparations that entire groups of cells are often active at the same time. This coordinated interaction of nerve ...

György. "We observed average editing rates of 75% in cone cells and 87% in retinal pigment epithelial cells. These results far exceed what we believe is necessary to provide clinical benefit to ...